Zusammenfassung
Hintergrund
BRAF-V600E-mutierte kolorektale Karzinome (KRK) sind mit 8–12 % aller KRK vergleichsweise selten. In der metastasierten Situation ist diese Mutation prognostisch sehr ungünstig.
Material und Methoden
Relevante Literatur wurde ausgewertet und zusammenfassend dargestellt.
Ergebnisse
Auch bei Behandlung mit intensivierter Chemotherapie sind die Überlebenszeiten von Patienten mit BRAF-V600E-mutierten Tumoren am geringsten von allen KRK-Subtypen.
Schlussfolgerung
Innovative Behandlungskonzepte, die sich auf unterschiedliche Komponenten des EGFR-RAS-RAF-MEK-ERK-Signalwegs richten, definieren einen neuen Therapiestandard für diese Subgruppe metastasierter KRK.
Abstract
Background
BRAFV600E-mutated colorectal cancer (CRC) is comparatively rare with an incidence of 8–12% of all CRCs. In the metastatic setting, this mutation is associated with a particularly poor prognosis.
Materials and methods
The relevant literature was evaluated and summarized.
Results
Even when treated with intensified chemotherapy, overall survival of patients with BRAFV600E-mutated mCRC is the poorest of all CRC subtypes.
Conclusion
Novel therapeutic concepts that target several components of the EGFR-RAS-RAF-MEK-ERK signaling pathway define a new treatment standard for this subgroup of metastatic CRCs.
Literatur
Robert Koch-Institut (2017) Krebs in Deutschland für 2013/2014 https://doi.org/10.17886/rkipubl-2017-007
Bruckner HW, Motwani BT (1991) Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 18(5):443–461
Tournigand C et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229–237
Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
Bokemeyer C et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5):663–671
Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastastic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol 15:1065–1075
Douillard JY et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11):1023–1034
Van Cutsem E et al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33(7):692–700
Tran B et al (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20):4623–4632
Tveit KM et al (2012) Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 30(15):1755–1762
Pietrantonio F et al (2015) Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 51(5):587–594
Venderbosch S et al (2014) Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 20(20):5322–5330
Deng G, Bell I, Crawley S et al (2004) BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:191–195
Samowitz WS, Sweeney C, Herrick J et al (2005) Poor survival associated with the BRAF V600E mutation in microsatellite stable colon cancers. Cancer Res 65(14):6063–6069
Cremolini C et al (2015) BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol 26(10):2092–2097
Loupakis F et al (2014) FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 50(1):57–63
Kopetz S et al (2015) Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 33(34):4032–4038
Samalin E, Bouche O, Thezenas S et al (2014) Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastastic colorectal cancer and KRAS-mutated tumours: a multicenter Phase I/II trial. Br J Cancer 110:1148–1154
Kopetz S, Desai J, Chan E et al (2015) Phase II pilot study of vemurafenib in patients with metastastic BRAF-mutated colorectal cancer. J Clin Oncol 33:4032–4038
Hyman DM, Puzanov I, Subbiah V et al (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726–736
Chen SH, Zhang Q, Van Horn RD et al (2016) Oncogenic BRAF deletions that function as homodimers and are sensitive ton inhibition by RAF dimer inhibitor LY3009120. Cancer Discov 6:300–315
Vakana E, Pratt S, Blosser W et al (2017) LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget 8:9251–9266
Corcoran RB, Atreya CE, Falchook GS et al (2015) Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 112:1921–1928
Corcoran RB, Ebi H, Turke AB et al (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227–235
Corcoran RB, Andre T, Attreya CE et al (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 8:428–443
Kopetz S, McDonough SL, Morris VK et al (2017) Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 35(Suppl 4S):520
Kopetz S, Grothey A, Yaeger E et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Eng J Med 381(17):1632–1643
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Güthle und T. Seufferlein geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Güthle, M., Seufferlein, T. Stellenwert der BRAF-Inhibition bei soliden Tumoren wie dem kolorektalen Karzinom. Onkologe 26, 708–712 (2020). https://doi.org/10.1007/s00761-020-00785-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-020-00785-8
Schlüsselwörter
- Intestinale Neoplasien
- Molekulare gezielte Therapie
- Antikörper, monoklonale, humanisierte
- BRAF-Protein, humanes
- Metastasierung